Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Cav-x
2. Difluoride, Tin
3. Difluorides, Tin
4. Floran
5. Florans
6. Fluoride, Stannic
7. Fluoride, Stannous
8. Fluoride, Tin
9. Fluorides, Stannic
10. Fluorides, Stannous
11. Fluorides, Tin
12. Fluoristan
13. Fluoristans
14. Gel-kam
15. Gel-tin
16. Omnii-gel
17. Omnii-med
18. Stanimax
19. Stanimaxs
20. Stannic Fluoride
21. Stannic Fluorides
22. Stannous Fluorides
23. Tetrafluoride, Tin
24. Tetrafluorides, Tin
25. Tin Difluoride
26. Tin Difluorides
27. Tin Fluoride
28. Tin Fluorides
29. Tin Tetrafluoride
30. Tin Tetrafluorides
1. Tin(ii) Fluoride
2. Tin Difluoride
3. 7783-47-3
4. Fluoristan
5. Difluorotin
6. Tin Bifluoride
7. Difluorostannylene
8. Snf2
9. Stannous Fluoride (usp)
10. Stannous Fluoride [usp]
11. Omnii-gel
12. Gel-kam
13. Easygel
14. Stancare
15. Stanide
16. Crest
17. Stop
18. Iradicar Snf2
19. Iradicav Snf2
20. King's Gel-tin
21. Cap-tin Mouthrinse
22. Stop Home Treatment
23. Iradicar Stannous Fluoride
24. Stannous Fluoride (snf2)
25. Tin Ii Fluoride
26. Hsdb 783
27. Tin(+2)fluoride
28. Stannous Difluoride
29. Gingimed (tn)
30. Einecs 231-999-3
31. Oral-b Rinsing Solution, Concentrate
32. Mfcd00042540
33. Tin (ii) Fluoride
34. Tin(ii) Fluoride, 99%
35. Unii-3ftr44b32q
36. Tin (ii) Fluoride, -4 Mesh
37. Chebi:135933
38. Db11092
39. Ft-0695303
40. D05919
41. A929354
42. Q204962
43. Samarium Barium Copper Oxide (sbco) Sputtering Targets
44. 4-chloro-2-pyridinemethanamine;(4-chloropyridin-2-yl)methanamine
| Molecular Weight | 156.71 g/mol |
|---|---|
| Molecular Formula | F2Sn |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 0 |
| Exact Mass | 157.899009 g/mol |
| Monoisotopic Mass | 157.899009 g/mol |
| Topological Polar Surface Area | 0 Ų |
| Heavy Atom Count | 3 |
| Formal Charge | 0 |
| Complexity | 2.8 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Stannous fluoride is applied directly to the surfaces of teeth in the form of solutions or gels for the prevention of dental caries in children.
American Hospital Formulary Service-Drug Information 88. Bethesda, MD: American Society of Hospital Pharmacists, 1988 (Plus supplements)., p. 2159
Dilute solutions of gels containing 0.4% stannous fluoride have been used to prevent decalcification in orthodonic patients and to protect against postirradiation caries.
American Hospital Formulary Service-Drug Information 88. Bethesda, MD: American Society of Hospital Pharmacists, 1988 (Plus supplements)., p. 2160
The ADA currently states that topical application of 8% aqueous solution of stannous fluoride at 6 to 12 month intervals is the preferred method of administration. Prior to topical application of the 8% solution, the teeth should be thoroughly cleaned, isolated with cotton rolls, and dried with compressed air. The teeth are then kept moist with a freshly prepared 8% solution of stannous fluoride for a 4 minute period. Topical application of 8% aqueous solutions of stannous fluoride should be repeated at 6 to 12 month intervals. Less concentrated solutions or gels of stannous fluoride may be applied topically daily or every other day with a toothbrush or as a rinsing solution. For self administration in adults and children 6 years of age and older, a 0.4% gel can be applied to the teeth and then thoroughly brushed once daily; the gel should then be allowed to remain on the teeth for 1 minute before expectorating. For self-administration of a 0.1% rinsing solution, 10 ml is generally administered once daily in adults and children 6 years of age and older ... .
American Hospital Formulary Service-Drug Information 88. Bethesda, MD: American Society of Hospital Pharmacists, 1988 (Plus supplements)., p. 2162
Staining or pigmentation (eg, yellow, brown, brown black) of the teeth resulting from topical application of concentrated solutions or gels of stannous fluoride has been reported, particularly in patients with poor oral hygiene. The pigmentation, which is probably stannous sulfide, is generally associated with a carious lesion or a hypocalcified area of the enamel or with plaque or accumulated debris, or occurs at the margin of a silicate restoration. Staining has also occurred with stannous fluoride containing dentifrices, but the risk of staining with these dentifrices appears to be less than that with stannous fluoride containing solutions or gels because the latter preparations do not contain abrasives, they are in contact with teeth for longer periods of time after application, and the mouth is not rinsed with water after application. To minimize the risk of staining, individuals receiving stannous fluoride containing preparations should be advised of the importance of good oral hygiene (eg, adequate brushing). These individuals should also be advised that such staining is not harmful or permanent and can be removed by a dentist or dental hygienist.
American Hospital Formulary Service-Drug Information 88. Bethesda, MD: American Society of Hospital Pharmacists, 1988 (Plus supplements)., p. 2160
Food and Environmental Agents: Effect on Breast-Feeding: Reported Sign or Symptom in Infant or Effect on Lactation: Fluorides: None. /from Table 7/
Report of the American Academy of Pediatrics Committee on Drugs in Pediatrics 93 (1): 142 (1994)
Indicated for use to relieve dental hypersensitivity, increase enamel production, prevent gingivitis and cavities, and control periodontal infections.
Stannous fluoride mediates both bactericidal and bacteriostatic properties and provides an anti-erosive action on tooth enamel.
Cariostatic Agents
Substances that inhibit or arrest DENTAL CARIES formation. (Boucher's Clinical Dental Terminology, 4th ed) (See all compounds classified as Cariostatic Agents.)
A - Alimentary tract and metabolism
A01 - Stomatological preparations
A01A - Stomatological preparations
A01AA - Caries prophylactic agents
A01AA04 - Stannous fluoride
Absorption
Tin is retained in the demineralized organic matrix to some extent, diffuses through the phosphorylated non-collagenous proteins in the dentine called phosphophoryn and accumulates in the underlying mineralized tissue.
Route of Elimination
Materials introduced into the oral cavity can be eliminated by salivary washout and swallowing, absorption through oral surfaces, or degradation.
Volume of Distribution
Stannous fluoride is cleared from saliva rapidly but very well retained in gingival plaque for a prolonged period of time.
Clearance
Stimulated and nonstimulated salivary elimination microrate constants in this case would be 1 and 0.5 min^1, respectively.
Fluoride ion is rapidly & extensively absorbed from the gut. In rats, absorption of sodium fluoride ... & stannous fluoride is similar.
IARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work). Available at: https://monographs.iarc.fr/ENG/Classification/index.php, p. V27 274 (1982)
Fluoride is transported in the blood in the free rather than the protein-bound form; it is distributed rapidly throughout all soft tissues but is not accumulated. /Fluoride ion/
IARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work). Available at: https://monographs.iarc.fr/ENG/Classification/index.php, p. V27 274 (1982)
THE PLACENTA OF RATS WAS PERMEABLE TO FLUORIDE @ 25 PPM IN DRINKING WATER JUST BEFORE OR DURING GESTATION. LESS THAN 1% ADMIN TO PREGNANT RATS WAS TRANSFERRED IN PROGENY, INDICATING STRONG DISCRIMINATION AGAINST TRANSPLACENTAL TRANSFER. NO DIFFERENCE IN THE TRANSFERRED AMT WAS OBSERVED WHEN FLUORIDE WAS GIVEN AS SODIUM FLUORIDE OR TIN FLUORIDE.
PMID:4511299 KATZ S, STOOKEY GK; J DENT RES 52 (2): 206-10 (1973)
THE FATE OF (113)TIN HAS BEEN EVALUATED IN THE RAT FOLLOWING THE ADMINISTRATION OF (113)TIN(II) AND (113)TIN(IV). CHANGING THE ANION COMPLEMENT FROM FLUORIDE TO CITRATE DID NOT AFFECT THE BIOLOGICAL FATE OF EITHER VALENCE FORM OF TIN. FROM A SINGLE PER ORAL DOSE OF 20 MG OF TIN(II) OR TIN(IV)/KG, 2.85 AND 0.64%, RESPECTIVELY, WERE ABSORBED. WITHIN 48 HR, ABOUT 50% OF THE ABSORBED TIN WAS EXCRETED. THE TISSUE DISTRIBUTION OF THE TIN REPORTED AS A PERCENT OF THE DOSED TIN(II) AND TIN(IV), RESPECTIVELY, WAS SKELETON 1.02 AND 0.24, LIVER 0.08 AND 0.02, AND KIDNEYS 0.09 AND 0.02. FROM A SINGLE IV DOSE OF 2 MG OF TIN(II) OR TIN(IV)/KG, ABOUT 30% WAS EXCRETED IN THE URINE; 11% OF THE TIN(II) WAS ELIMINATED IN THE BILE, BUT NONE OF THE TIN(IV). THE AVERAGE PERCENT OF TIN ABSORBED DURING A 28-DAY PER ORAL DOSING STUDY WAS LESS THAN FROM A SINGLE PER ORAL DOSE. IN A COMPARISON OF THE TIN IN TISSUES FROM A SINGLE AND FROM A 28-DAY PER ORAL DOSING, ONLY BONE HAD AN INCREASED ACCUMULATION APPROXIMATELY PROPORTIONAL TO THE INCREASED AMOUNT OF SYSTEMIC EXPOSURE.
PMID:4850377 HILES RA; TOXICOL APPL PHARMACOL 27 (2): 366 (1974)
For more Absorption, Distribution and Excretion (Complete) data for STANNOUS FLUORIDE (7 total), please visit the HSDB record page.
The half-life for the decay of the salivary elimination rate constant was 13 min.
THE FATE OF (113)TIN HAS BEEN EVALUATED IN THE RAT FOLLOWING THE ADMINISTRATION OF (113)TIN(II) AND (113)TIN(IV). ... THE BIOLOGICAL HALF-LIFE OF THE TIN IN BONES WAS CALCULATED TO BE 20 TO 40 DAYS.
PMID:4850377 HILES RA; TOXICOL APPL PHARMACOL 27 (2): 366 (1974)
Stannous fluoride has been shown to manage and prevent dental caries and gingivitis by promoting enamel mineralization, reducing gingival inflammation and bleeding, its potential broad-spectrum antibiotic effect, and through modulation of the microbial composition of the dental biofilm. It works by depositing a stable acid-resistant layer on the tooth surfaces which is composed of calcium fluoride produced when stannous fluoride converts the calcium mineral apatite into fluorapatite. Tin and fluoride mediate anti-erosive actions by interacting with and modifying the absorbent layer composed of salivary proteins such as mucins, perhaps by enhancing the cross-linking between the proteins to result in a more resistant and protective layer against erosion. The efficacy of stannous fluoride solutions seems to depend mainly on the incorporation of tin in the mineralized dentine when the organic portion is preserved but on surface precipitation when the organic portion is continuously digested. Moreover, the relative erosion-inhibiting effects of stannous fluoride strongly depend on the presence or absence of the demineralized organic dentine matrix.
DENTAL STUDENTS RINSED FOR 4 DAYS WITH 0.2% AQ SOLN STANNOUS FLUORIDE OR STANNIC TETRACHLORIDE & IN ADDITION 15% SUCROSE TO ENHANCE PLAQUE FORMATION. TIN(2+) SHOWED MARKED INHIBITING ACTIVITY WHEREAS THE TIN(4+) SHOWED ONLY SLIGHT EFFECT. THE TIN(2+) ION ALSO REDUCED THE ACIDOGENICITY OF THE DENTAL PLAQUE WHEREAS THE TIN(4+) SHOWED NO EFFECT. TIN(2+) REDUCES METABOLIC ACTIVITY OF PLAQUE BY OXIDIZING THIOL GROUPS BY AFFINITY FOR THEM. THIS IS NOT THE CASE FOR TIN(4+).
PMID:7008492 ELLINGSEN JE ET AL; ACTA ODONTOL SCAND 38 (4): 219-22 (1980)
/STANNOUS FLUORIDE/ ... ALTERS THE COMPOSITION & CRYSTALLINE STRUCTURE OF THE HYDROXYAPATITE-LIKE SALTS THAT MAKE UP THE BULK OF ENAMEL, ESPECIALLY, & DENTIN, SO THAT THE TOOTH MATERIAL IS MORE RESISTANT TO ACIDIC EROSION & DENTAL CARIES (DECAY).
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 727
When stannous fluoride is applied topically to teeth, a highly adherent surface coating composed mainly of tin phosphate and smaller amounts of calcium fluoride and a tin hydroxyorthophosphate is formed on enamel.
American Hospital Formulary Service-Drug Information 88. Bethesda, MD: American Society of Hospital Pharmacists, 1988 (Plus supplements)., p. 2159
IN A STANDARDIZED RABBIT MODEL, YELLOW GOLDEN STAIN FORMED ON TOOTH SURFACES DURING USE OF STANNOUS FLUORIDE IS DUE TO ITS LOW PH WHICH CAUSES DENATURATION OF PELLICLE PROTEIN WITH EXPOSURE TO SULFHYDRYL GROUPS, WHICH FORM STANNIC SULFIDES THROUGH REACTIONS WITH TIN(2+).
PMID:6952551 ELLINGSEN JE ET AL; SCAND J DENT RES 90 (1): 9-13 (1982)
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 475
Submission : 1962-03-23
Status : Inactive
Type : II

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 731
Submission : 1963-08-06
Status : Inactive
Type : II

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
NDC Package Code : 42402-101
Start Marketing Date : 2012-10-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF

NDC Package Code : 82807-001
Start Marketing Date : 2021-12-15
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER, FOR SOLUTION (1kg/kg)
Marketing Category : BULK INGREDIENT

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 731
Submission : 1963-08-06
Status : Inactive
Type : II

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 475
Submission : 1962-03-23
Status : Inactive
Type : II

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC Package Code : 82807-001
Start Marketing Date : 2021-12-15
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER, FOR SOLUTION (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 42402-101
Start Marketing Date : 2012-10-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]About the Company : Incorporated in 2011, SNA Health Care Pvt. Ltd., a WHO-GMP Certified API Manufacturing Company involved in the manufacture and export of Active Pharmaceutical Ingredients, Pharmace...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Stannous Fluoride is a small molecule drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Dental Calculus.
Lead Product(s): Tin Fluoride,Inapplicable
Therapeutic Area: Dental and Oral Health Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 31, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tin Fluoride,Inapplicable
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of Stannous Fluoride Toothpaste vs Regular Fluoride Toothpaste
Details : Stannous Fluoride is a small molecule drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Dental Calculus.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 31, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Stannous Fluoride is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Halitosis.
Lead Product(s): Tin Fluoride,Inapplicable
Therapeutic Area: Dental and Oral Health Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 31, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tin Fluoride,Inapplicable
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Study on Efficacy of New Toothpaste in Bangkok Participants
Details : Stannous Fluoride is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Halitosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 31, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Stannous Fluoride is a Miscellaneous drug candidate, which is currently being evaluated in Undisclosed clinical studies for the treatment of Dentin Sensitivity.
Lead Product(s): Tin Fluoride,Potassium Nitrate
Therapeutic Area: Dental and Oral Health Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 10, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tin Fluoride,Potassium Nitrate
Therapeutic Area : Dental and Oral Health
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Study to Investigate the Antihypersensitivity Efficacy of a Novel Dentifrice
Details : Stannous Fluoride is a Miscellaneous drug candidate, which is currently being evaluated in Undisclosed clinical studies for the treatment of Dentin Sensitivity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 10, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Stannous Fluoride is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Undisclosed clinical studies for the treatment of Dental Plaque.
Lead Product(s): Tin Fluoride,Zinc Dichloride
Therapeutic Area: Dental and Oral Health Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 11, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tin Fluoride,Zinc Dichloride
Therapeutic Area : Dental and Oral Health
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Stannous Fluoride is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Undisclosed clinical studies for the treatment of Dental Plaque.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 11, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Stannous Fluoride is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Gingivitis.
Lead Product(s): Tin Fluoride,Fluorophosphate
Therapeutic Area: Dental and Oral Health Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 05, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tin Fluoride,Fluorophosphate
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Assessing Gingivitis and Plaque From a Marketed Toothpaste
Details : Stannous Fluoride is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Gingivitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 05, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Stannous Fluoride is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Gingivitis.
Lead Product(s): Tin Fluoride,Inapplicable
Therapeutic Area: Dental and Oral Health Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: University of Texas Health Science Center at Houston
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 12, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tin Fluoride,Inapplicable
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : University of Texas Health Science Center at Houston
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Stannous Fluoride is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Gingivitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 12, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Sodium Monofluorophosphate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Gingivitis.
Lead Product(s): Fluorophosphate,Tin Fluoride
Therapeutic Area: Dental and Oral Health Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 08, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Fluorophosphate,Tin Fluoride
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluating Gingivitis and Systemic Biomarkers
Details : Sodium Monofluorophosphate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Gingivitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 08, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Stannous Fluoride is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Dental Plaque.
Lead Product(s): Tin Fluoride,Cetylpyridinium Chloride
Therapeutic Area: Dental and Oral Health Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 26, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tin Fluoride,Cetylpyridinium Chloride
Therapeutic Area : Dental and Oral Health
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Stannous Fluoride is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Dental Plaque.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 26, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Stannous Fluoride is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Gingival Diseases.
Lead Product(s): Tin Fluoride,Inapplicable
Therapeutic Area: Dental and Oral Health Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 26, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tin Fluoride,Inapplicable
Therapeutic Area : Dental and Oral Health
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Brief Title: a Clinical Study to Assess Gingivitis
Details : Stannous Fluoride is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Gingival Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 26, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Stannous Fluoride is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dental Plaque.
Lead Product(s): Tin Fluoride,Inapplicable
Therapeutic Area: Dental and Oral Health Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 24, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tin Fluoride,Inapplicable
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Stannous Fluoride is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dental Plaque.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 24, 2024

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Tin Colloid
Dosage Form : INJ
Dosage Strength : 0.13mg/vial
Packaging : 5X1mg/vial
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Tin Colloid
Dosage Form : INJ
Dosage Strength : 0.13mg/vial
Packaging : 5X1mg/vial
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Dosage Form : Tablet
Grade : Oral
Dosage Form : Cream / Lotion / Ointment
Grade : Topical, Parenteral
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Dosage Form : Suspension
Grade : Oral
Dosage Form : Capsule
Grade : Topical, Oral
Dosage Form : Cream / Lotion / Ointment
Grade : Topical, Oral
Dosage Form : Suspension
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Dosage Form : Suspension
Grade : Oral
Dosage Form : Cream / Lotion / Ointment
Grade : Topical
Dosage Form : Capsule
Grade : Oral
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Dosage Form : Suspension
Grade : Oral
Application : Rheology Modifiers
Excipient Details : Blanose CMC 7MF is used as a thickener and viscosity modifier in liquid formulations such as suspensions.
Dosage Form : Suspension
Grade : Oral
Dosage Form : Suspension
Grade : Oral
Dosage Form : Suspension
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Application : Emulsifying Agents
Excipient Details : HDK N20 Pharma is used as a pharmaceutical emulsifying agent in tablets, capsules, syrups, and solutions.
Dosage Form : Syrup
Grade : Oral
Application : Taste Masking
Excipient Details : Insoluble saccharin (Q-0350, 15-191201) is used as an artificial sweetener in syrups, liquids, suspensions, mouthwashes, and tablets.
Pharmacopoeia Ref : USP/NF, JP, Kosher, ISO, Halal...
Technical Specs : Min. 98% Purity
Ingredient(s) : Saccharin Excipient
Dosage Form : Suspension
Grade : Topical
Application : Rheology Modifiers
Excipient Details : Silfoam® SE 2 is used as a thickener and a viscosity modifier in liquid and topical dosage forms.
Dosage Form : Syrup
Grade : Oral
Application : Taste Masking
Excipient Details : Sodium Saccharin (Q-0300, 15-191201) is used as an artificial sweetener in tablets, syrup, suspensions, liquids, and mouthwashes.
Pharmacopoeia Ref : USP/NF, JP, Kosher, ISO, Halal...
Technical Specs : 15% MOISTURE, Min. 98% Purity
Ingredient(s) : Sodium Saccharin Excipient
Dosage Form : Emulsion
Grade : Topical
Application : Topical
Excipient Details : Triethanolamine is widely used in topical pharmaceutical formulations primarily in the formation of emulsions and sunscreen.
Dosage Form : Suspension
Grade : Topical, Oral
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Dosage Form : Granule / Pellet
Grade : Not Available
Brand Name : Kollicoat SR 30 D
Application : Taste Masking
Excipient Details : pH-independent sustained release coating for small particles, pellets, granules and tablets. Sprayable polymeric film former. Flexible. Wash resistant.
Pharmacopoeia Ref : Ph. Eur.: Poly(vinyl acetate) ...
Technical Specs : Not Available
Ingredient(s) : Sodium Lauryl Sulfate
Dosage Form : Tablet
Grade : Not Available
Application : Granulation
Excipient Details : For non-erodible matrices using direct compression, Controlled release matrix. Matrix former in transdermal patches and topical films.
Pharmacopoeia Ref : Ph. Eur., USP-NF, JP-JPE: 80 %...
Technical Specs : Not Available
Ingredient(s) : Hydrated Silica
Dosage Form : Emulsion
Grade : Not Available
Application : Topical
Excipient Details : Self-emulsifying and consistency building, easy-to-use base for dermatological creams
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Sodium Lauryl Sulfate
Dosage Form : Emulsion
Grade : Not Available
Application : Solubilizers
Excipient Details : Polymeric solubilizer, emulsifier & plasticizer, enhances viscosity, thermoreversible gelling effect.
Pharmacopoeia Ref : Ph. Eur., USP-NF: Poloxamer 40...
Technical Specs : Not Available
Ingredient(s) : Poloxamer 407
Dosage Form : Tablet
Grade : Not Available
Application : Granulation
Excipient Details : Wetting agent, reduces disintegration time, Ionic solubilizer, high HLB anionic emulsifier for semi-solids and foams.
Pharmacopoeia Ref : Ph. Eur.: Sodium Laurilsulfate...
Technical Specs : Not Available
Ingredient(s) : Sodium Lauryl Sulfate
Dosage Form : Tablet
Grade : Not Available
Brand Name : Kolliphor SLS Fine
Application : Granulation
Excipient Details : Wetting agent, reducing disintegration time, direct compression, Hydrophilic lubricant, effervescent tablets.
Pharmacopoeia Ref : Ph. Eur.: Sodium Laurilsulfate...
Technical Specs : Not Available
Ingredient(s) : Sodium Lauryl Sulfate
Dosage Form : Emulsion
Grade : Not Available
Brand Name : Kollisolv PEG 300
Application : Solubilizers
Excipient Details : Liquid plasticizer, solvent for oral and topical applications, hydrophilic fill for solubilization of hydrophilic APIs.
Pharmacopoeia Ref : Ph. Eur., JP, FCC, USP
Technical Specs : Not Available
Ingredient(s) : Polyethylene Glycol Excipient
Dosage Form : Tablet
Grade : Not Available
Brand Name : Kollisolv PEG 400
Application : Solubilizers
Excipient Details : Liquid plasticizer, Solvent for oral and topical applications, Hydrophilic fill for solubilization of hydrophilic APIs.
Pharmacopoeia Ref : Ph. Eur., JP, FCC, USP
Technical Specs : Not Available
Ingredient(s) : Polyethylene Glycol Excipient
Dosage Form : Softgel Capsule
Grade : Not Available
Brand Name : Kollisolv PEG 600
Application : Solubilizers
Excipient Details : Hydrophilic fill for solubilization of hydrophilic APIs.
Pharmacopoeia Ref : Ph. Eur., JP, FCC, USP
Technical Specs : Not Available
Ingredient(s) : Polyethylene Glycol Excipient
Dosage Form : Tablet
Grade : Not Available
Application : Film Formers & Plasticizers
Excipient Details : Liquid plasticizer with high ADI, hydrophilic solvent & humectant in emulsions, skin penetration enhancer in topical formulaitons.
Pharmacopoeia Ref : Ph. Eur., JP, FCC, USP
Technical Specs : Not Available
Ingredient(s) : Propylene Glycol
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Dosage Form : Syrup
Grade : Not Available
Application : Taste Masking
Pharmacopoeia Ref : Not Available
Technical Specs : Pharma Grade/Food Grade
Ingredient(s) : Sorbitol
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Market Place
ABOUT THIS PAGE
85
PharmaCompass offers a list of Tin Fluoride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Tin Fluoride manufacturer or Tin Fluoride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Tin Fluoride manufacturer or Tin Fluoride supplier.
PharmaCompass also assists you with knowing the Tin Fluoride API Price utilized in the formulation of products. Tin Fluoride API Price is not always fixed or binding as the Tin Fluoride Price is obtained through a variety of data sources. The Tin Fluoride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Stannous Fluoride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Stannous Fluoride, including repackagers and relabelers. The FDA regulates Stannous Fluoride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Stannous Fluoride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Stannous Fluoride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Stannous Fluoride supplier is an individual or a company that provides Stannous Fluoride active pharmaceutical ingredient (API) or Stannous Fluoride finished formulations upon request. The Stannous Fluoride suppliers may include Stannous Fluoride API manufacturers, exporters, distributors and traders.
click here to find a list of Stannous Fluoride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Stannous Fluoride DMF (Drug Master File) is a document detailing the whole manufacturing process of Stannous Fluoride active pharmaceutical ingredient (API) in detail. Different forms of Stannous Fluoride DMFs exist exist since differing nations have different regulations, such as Stannous Fluoride USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Stannous Fluoride DMF submitted to regulatory agencies in the US is known as a USDMF. Stannous Fluoride USDMF includes data on Stannous Fluoride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Stannous Fluoride USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Stannous Fluoride suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Stannous Fluoride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Stannous Fluoride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Stannous Fluoride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Stannous Fluoride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Stannous Fluoride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Stannous Fluoride suppliers with NDC on PharmaCompass.
Stannous Fluoride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Stannous Fluoride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Stannous Fluoride GMP manufacturer or Stannous Fluoride GMP API supplier for your needs.
A Stannous Fluoride CoA (Certificate of Analysis) is a formal document that attests to Stannous Fluoride's compliance with Stannous Fluoride specifications and serves as a tool for batch-level quality control.
Stannous Fluoride CoA mostly includes findings from lab analyses of a specific batch. For each Stannous Fluoride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Stannous Fluoride may be tested according to a variety of international standards, such as European Pharmacopoeia (Stannous Fluoride EP), Stannous Fluoride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Stannous Fluoride USP).